Updated: A GPCR startup out of France and Canada scores its Series A after 14 years of wheeling and dealing

Paul Schloesser

Associate Editor

Having already nailed down multiple licensing and collaboration deals with Big Pharma giants like Bristol Myers Squibb and Pfizer, a France- and Quebec-based GPCR biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: A GPCR startup out of France and Canada scores its Series A after 14 years of wheeling and dealing

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Vertex makes money from sickle cell therapy Casgevy

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Up­dat­ed: A GPCR start­up out of France and Cana­da scores its Se­ries A af­ter 14 years of wheel­ing and deal­ing

Associate Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Updated: A GPCR startup out of France and Canada scores its Series A after 14 years of wheeling and dealing